Illumina (NASDAQ:ILMN) CAO Sells 500 Shares

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 500 shares of Illumina stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at $2,311,360. This represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Up 0.9%

Illumina stock traded up $1.44 during mid-day trading on Monday, hitting $164.40. The company had a trading volume of 2,190,398 shares, compared to its average volume of 1,870,274. The stock’s 50 day moving average price is $133.73 and its two-hundred day moving average price is $132.09. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $24.87 billion, a PE ratio of 29.89, a price-to-earnings-growth ratio of 2.70 and a beta of 1.50. Illumina, Inc. has a 12 month low of $78.79 and a 12 month high of $165.97.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business posted $0.97 earnings per share. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ILMN shares. Daiwa Securities Group raised Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research note on Thursday, May 14th. Guggenheim boosted their target price on Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Monday. Barclays increased their target price on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Evercore reissued an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Finally, Citigroup lifted their price target on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $138.38.

Institutional Trading of Illumina

A number of institutional investors have recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Illumina by 7.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after purchasing an additional 79 shares in the last quarter. HighPoint Advisor Group LLC grew its holdings in shares of Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 80 shares during the period. Meeder Advisory Services Inc. boosted its holdings in shares of Illumina by 3.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after buying an additional 85 shares in the last quarter. Toronto Dominion Bank boosted its holdings in Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after acquiring an additional 92 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after purchasing an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.